Hemorrhage is a primary cause of mortality in trauma patients even though most injuries suffered are potentially survivable. Increasing survival is simply a matter of effectively controlling hemorrhage. Current hemostatic dressings range from simple gauze to aluminosilicates from natural or synthetic clay Combat GauzeTM, or chitosan from shellfish or algae (CeloxTM). These dressings stop the bleeding by direct compression of injured vessels and/or activation of the intrinsic coagulation pathway. In trauma patients however, this system is often compromised.
Current dressings are also unstable, which increases the chance of rebleeding due to movement. The next generation of advanced dressings will likely incorporate plasma-coagulation factors such as fibrinogen that would directly form fibrin clots and seal injured vessels. Hemostasis would be independent of a person’s injuries, and re-bleeding would be less likely also.
St. Teresa Medical, Inc., a medical device company in Minnesota, is commercializing this kind of hemostatic technology platform called FASTCLOT®. The patent-pending FASTCLOT products use an electrospun nano-fiber dextran matrix carrier along with fibrin producing proteins such as thrombin and fibrinogen. The carrier in all FASTCLOT products dissolves in seconds to minutes when in contact with fluid, effectively releasing the clot forming proteins at the bleeding site. As a result, the clotting cascade is accelerated, generating a quick and robust clot in both arterial and venous bleeding, preventing excess blood loss. Most importantly, the FASTCLOT platform technology is the only completely dissolvable and absorbable fibrin sealant that will be available in the market. As opposed to other fibrin sealants, FASTCLOT products leave nothing behind in the patient’s body, eliminating the risk for scarring, inflammation and re operative surgery.
The FASTCLOT technology was developed by a research team at Virginia Commonwealth University and is exclusively licensed by St Teresa Medical. The company is developing products for both surgery (SURGICLOT®) and trauma (WRAPCLOT®), for civilian and military markets. St. Teresa Medical also owns a subsidiary, St. Francis Veterinary Medical, where the product ANIMALCLOT® designed for animal use and developed using the same FASTCLOT technology is currently being sold.
Fibrin dressings have great life-saving potential but their use is limited by availability, cost and safety. CEO and co-founder Phil Messina said St Teresa Medical products can overcome these limitations. St Teresa has completed several pre-clinical animal studies demonstrating the safety and efficacy of the technology. All studies indicated no allergic, immunogenic or thrombolytic events. The FASTCLOT products are reliable, robust and inexpensive hemostatic agents, Messina said.
“We create value for the patient, surgeon, hospital and payer delivering better clinical outcomes,” he said.
St. Teresa Medical products have an estimated global market potential of several billion dollars. Surgical applications represent the single largest market. The company has raised up to $4 million since its inception. St Teresa Medical expects a CE Mark approval on its SURGICLOT fibrin sealant in mid 2014 in Europe and subsequent approval in the US through a Biologics License Application (BLA) submission approximately 18 months later.
No comments:
Post a Comment